Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
25311
Description
Study part: Exclusion Criteria Screening. A Single Blind, Parallel Group, Up-titration, Phase 1 Study in Healthy Volunteers to Determine a Starting Dose and Select an Up-titration Regimen for a new Formulation of Ropinirole. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Phase: phase 1. Study Recruitment Status: Completed Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/201. Clinical Study ID: 101468/201
Mots-clés
Versions (2)
- 01/09/2017 01/09/2017 -
- 23/04/2019 23/04/2019 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
1 septembre 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Exclusion Criteria Screening Ropinirole Restless Legs Syndrome 101468/201
Exclusion Criteria Screening
- StudyEvent: ODM
Similar models
Exclusion Criteria Screening
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Identification number
Item
Volunteer panel number
integer
C1300638 (UMLS CUI [1])
Subject number
Item
Subject number
integer
C2348585 (UMLS CUI [1])
number of cigarettes per day
Item
1. Subjects who smoke more than 10 cigarettes per day.
boolean
C3694146 (UMLS CUI [1])
comorbidity cardiovascular, neurological
Item
2. History or presence of clinically significant cardiovascular, neurological, psychiatric, haematological or renal abnormalities.
boolean
C0009488 (UMLS CUI [1,1])
C3887460 (UMLS CUI [1,2])
C2707261 (UMLS CUI [1,3])
C3887460 (UMLS CUI [1,2])
C2707261 (UMLS CUI [1,3])
postural hypotension
Item
3. History of postural hypotension or faints.
boolean
C0020651 (UMLS CUI [1])
Comorbidity Interferes with drug metabolism
Item
4. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
boolean
C0009488 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C0521102 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
medication
Item
5. The subject has received prescribed medication within 14 days or over-the-counter (OTC) medicine within 7 days before the first dosing day (apart from medications that are described below), which in the opinion of the Principal Investigator may interfere with the study procedures or compromise a subjects’ safety. Subjects who have taken OTC medication (apart from CYP1A2 medications, see below) may still be entered into the study, if, in the opinion of the Principal/Co-investigator in agreement with the Sponsor, the medication received will not interfere with the study procedures or compromise subjects’ safety.
boolean
C0013227 (UMLS CUI [1])
Item
6. Women on HRT treatments during which the proportions of oestrogen and progesterone are not kept constant throughout their 28-day cycle. e.g. some cyclic HRT treatments.
text
C0279025 (UMLS CUI [1])
Code List
6. Women on HRT treatments during which the proportions of oestrogen and progesterone are not kept constant throughout their 28-day cycle. e.g. some cyclic HRT treatments.
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
NA (NA)
drug dose
Item
7. Withdrawal, introduction, or change in dose of any drug known to substantially inhibit CYP1A2 (e.g., ciprofloxacin, fluvoxamine, cimetidine, ethinyloestradiol) or induce CYP1A2 (e.g., tobacco, omeprazole) within 7 days prior to first day of dosing. Subjects who are on stable doses (no change within 7 days of 1 st dose) of any CYP1A2 medications are permitted to participate, if, in the opinion of the Principal investigator and in agreement with the Sponsor, the medication received will not interfere with the study procedures or compromise subjects’ safety.
boolean
C0678766 (UMLS CUI [1])
Item
8. Pregnancy and/or breast-feeding.
text
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
NA (NA)
Item
9. Females of child-bearing potential who are not practicing a clinically accepted method of contraception such as surgical sterilization, I.U.D., diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception (i.e., Norplant ® ).
text
C3831118 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
Code List
9. Females of child-bearing potential who are not practicing a clinically accepted method of contraception such as surgical sterilization, I.U.D., diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception (i.e., Norplant ® ).
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
NA (NA)
Item
10. Female subjects with positive urine/serum pregnancy test result at screening or prior to first dose.
text
C0240802 (UMLS CUI [1])
Code List
10. Female subjects with positive urine/serum pregnancy test result at screening or prior to first dose.
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
NA (NA)
substance use disorder
Item
11. Recent history (within the last 6 months), or suspicion, of drug dependence or a positive screening or pre-dose drugs of abuse screen.
boolean
C0038586 (UMLS CUI [1])
alcohol abuse
Item
12. Abuse of alcohol (defined as an average weekly intake of greater than 21 units or an average daily intake greater than 3 units for men; greater than 14 units per week or greater than 2 units per day for women. One unit is equivalent to half a pint of beer, one measure of spirits or one glass of wine) or a positive screening or pre-dose alcohol test.
boolean
C0085762 (UMLS CUI [1])
hepatitis B surface antigen hepatitis C antibody positive; HIV Antibodies
Item
13. Positive pre-study screening result for hepatitis B surface antigen, hepatitis C antibody or HIV-1/2 antibodies.
boolean
C0019168 (UMLS CUI [1,1])
C0281863 (UMLS CUI [1,2])
C0019683 (UMLS CUI [2])
C0281863 (UMLS CUI [1,2])
C0019683 (UMLS CUI [2])
study subject participation status; blood donation
Item
14. Participation in another clinical trial, blood donation or blood loss less than 90 days before the present study.
boolean
C2348568 (UMLS CUI [1])
C0005794 (UMLS CUI [2])
C0005794 (UMLS CUI [2])
hypersensitivity
Item
15. Definite or suspected personal history or family history of adverse reactions or hypersensitivity to the study drug or to drugs with a similar chemical structure.
boolean
C0020517 (UMLS CUI [1])